Project Grant R01HL179221
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $637K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This $888,836 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by The Children's Hospital of Philadelphia (CHOP) to develop gene therapy approaches for treating hemophilia A. The key objectives are to: 1) Target factor VIII expression to liver sinusoidal endothelial cells (LSECs) rather than hepatocytes using genome editing and AAV gene addition methods, and 2) Compare the biological effects of expressing...
- This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research), provides $787,021 to The Leland Stanford Junior University (Stanford University) from September 20, 2025 through June 30, 2030. The grant supports research aimed at understanding the mechanisms of Factor VIII inhibitor formation in persons with hemophilia A, with the long-term goal of developing targeted therapies to prevent inhibitor development during early...
- This Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University aims to define the key cellular components and early immunologic events that mediate factor VIII immunity in persons with hemophilia A. The research will investigate the role of type 2 conventional dendritic cells (CDC2) in the development of anti-factor VIII antibodies, with the long-term goal of developing targeted...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 in funding to Bloodworks, a non-profit organization based in Seattle, Washington. The award, effective March 1, 2025 through February 28, 2032, supports molecular and translational research studies focused on hematological disorders, specifically von Willebrand disease and sickle cell disease. The research aims to...
- This Project Grant award for $445,000.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research conducted by The Children's Hospital of Philadelphia (CHOP) to study the role of neutrophil extracellular traps (NETs) in inflammatory and thrombotic diseases. The project aims to characterize the role of NETs in immune homeostasis, determine the mechanisms by which NET stabilization...
- This $457,514 Project Grant award was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Thomas Jefferson University, doing business as Sidney Kimmel Medical College. The grant funding supports research to investigate the role of platelet activation in maintaining hemostasis and reducing bleeding in coagulation disorders. The proposed studies will explore mechanisms by which reduced thrombin production limits platelet-mediated hemostatic...
- This Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) aims to advance scientific understanding of von Willebrand factor and von Willebrand disease. The $2,363,224 award to The Washington University, effective May 15, 2025 through April 30, 2030, supports a program project consisting of 4 research projects and 3 supporting cores. The key products and services to be delivered under this grant include: Identifying common...
- This Project Grant award for $314,363, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy technology called STITCHR to enable full gene replacement for Hemophilia A. The proposed research will engineer robust adeno-associated virus (AAV) constructs to deliver and express the full-length Factor VIII gene, addressing the limitations of current truncated versions. The project will...
- The U.S. National Heart Lung and Blood Institute awarded a Project Grant totaling $1,474,222.00 under the Cardiovascular Diseases Research program (CFDA 93.837) to The Medical College of Wisconsin, Inc. The grant funding supports research to investigate the relationship between low-density lipoprotein (LDL) cholesterol levels and hemostasis in patients with hemophilia A. Specifically, the research aims to explore how lower LDL cholesterol in hemophilia patients may lead to reduced von Willebrand...